TITLE

Mutations in a Molecule: The Virtues of Antagonism

AUTHOR(S)
Kharasch, Evan D.
PUB. DATE
October 2008
SOURCE
Mayo Clinic Proceedings;Oct2008, Vol. 83 Issue 10, p1083
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The author reflects on mutations in a molecule and the virtues of antagonism in clinical trials. He notes that drug development evolved through eras of natural product use, serendipitous discovery, national drug design and drug discovery. He found the discovery and development stories of methyl-naltrexone and alvimopan fascinating and provide an interesting perspective on modern drug development.
ACCESSION #
34633267

 

Related Articles

  • The Fine Art of Fine-Tuning Drug Formulation. Canavan, Neil // Drug Discovery & Development;Sep2005, Vol. 8 Issue 9, p26 

    Talks about the difficulties of drug development through clinical trials and the challenges emerge surrounding optimal drug formulation. Number of formulations that researchers have experimented; Administration of drugs; Determination of the responses of patients to various drug formulations. ...

  • A Call to Restructure the Drug Development Process: Government Over-regulation and Non-innovative Late Stage (Phase III) Clinical Trials are Major Obstacles to Advances in Health Care. Jones, Thomas C. // Science & Engineering Ethics;Oct2005, Vol. 11 Issue 4, p575 

    The history of drug/vaccine development has included major advances guided primarily by risk/benefit analyses concerning the innovative agent, not by evidence-based clinical trials (Phase I-IV). Because the approval for new drugs is hindered under the present process, the system requires...

  • Can drugs help premature ejaculation patients? Gebhart, Fred // Drug Topics;6/7/2004, Vol. 148 Issue 11, p28 

    This article reports that the strategy that transformed erectile dysfunction from an embarrassing problem to a treatable condition is now being applied to the issue of premature ejaculation. Research grants and marketing dollars from the Johnson and Johnson company are moving premature...

  • Are Development Times For Pharmaceuticals Increasing Or Decreasing? Keyhani, Salomeh; Diener-West, Marie; Powe, Neil // Health Affairs;Mar/Apr2006, Vol. 25 Issue 2, p461 

    This study examines trends in drug development times. Longer clinical trial times have been described as one factor leading to higher drug prices. Previous reports on development times have been based on proprietary data. We examined trends in development times for 168 drugs with data collected...

  • Antimalarials: Joint attack on malaria. Ellis, Clare // Nature Reviews Drug Discovery;Sep2004, Vol. 3 Issue 9, p735 

    Reports that a multidisciplinary team of scientists have developed an antimalarial drug candidate that will move into human clinical trials in late 2004. Publication of the researchers' work in the journal "Nature"; Overview of the disease; Selection of the drug candidate.

  • Toxicology and Pharmacology: Outsourcing, History, Process and Regulation; Technical, Political and Economic Challenges.  // Biomedical Market Newsletter;10/31/2011, Vol. 21, p581 

    The article reports on the addition of the "Toxicology and Pharmacology: Outsourcing, History, Process and Regulation: Technical, Political and Economic Challenges" report to the Research & Markets Ltd.'s offerings in Dublin, Ireland. The report features clinical trials and drug development...

  • Tested on humans.  // New Scientist;1/21/2006, Vol. 189 Issue 2535, p6 

    This article reports that human guinea pigs could soon be testing small quantities of experimental drugs, making it quicker and easier to weed out those that don't work. Nine out of ten experimental drugs don't make it to market because of biochemical reactions that didn't surface in the animal...

  • Pseudoreceptor models in drug design: bridging ligand- and receptor-based virtual screening. Tanrikulu, Yusuf; Schneider, Gisbert // Nature Reviews Drug Discovery;Aug2008, Vol. 7 Issue 8, p667 

    Rational drug design is based on explicit or implicit structure–activity relationship models. Typically, receptor-based or ligand-based strategies are pursued, depending on the information available about known ligands and the receptor structure. Pseudoreceptor models combine the...

  • Innovation-Focused Clinical Trials: New Strategies and Business Models in Drug Development. Dietlin, Tim // Bio Partnerships Asia;Mar2012, Vol. 4 Issue 3, p5 

    The article focuses on the effort of biopharmaceutical firms to adopt new strategies and business models in drug development. The clinical research organization (CRO) industry has designed more sophisticated infrastructure, methods, and talents which are difficult for sponsors to replicate...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics